Generation and Expansion of Human Cardiomyocytes from Patient Peripheral Blood Mononuclear Cells
February 12th, 2021
Here, we present a protocol to robustly generate and expand human cardiomyocytes from patient peripheral blood mononuclear cells.
This is comprehensive protocol facilities, raw boosts generation, and use pouncing of patient specific, cultures from peripheral blood mononuclear cells. This tactics are reproducible and easy to follow, specially for beginners. And don't require, special expertize in stem cell ballads, or cardiovascular medicine.
Our protocol can be used to generate patient specific cardiomyocytes from a single blood draw that can be used for modeling cardiovascular diseases and testing the cardiac toxicity of novel drugs. This protocol requires a long time commitment to stem cell reprogramming maintenance and directed differentiation. However, you really appreciate your endeavors.
When you see beating cardiomyocytes in the dish. When the human iPSC colonies reach over 90%confluency, rinse each well with three milliliters of DPBS before treating the cells with one milliliter of 0.5 millimolar EDTA in DPBS per well at 37 degrees Celsius. After five to eight minutes, add one milliliter of iPSC passaging medium to each well and manually dislodge the cells.
Transfer 600 to 900 microliters of the cells to individual Wells have a basement membrane coated six well plate for an overnight incubation at 37 degrees Celsius and 5%carbon dioxide. Then refresh the cultures with two milliliters of complete E8 medium every day for three to four days. When the culture's reached confluency, replace the medium with two milliliters of cardiomyocyte differentiation medium, two per well.
On day two, replace the supernatants with two milliliters of cardiomyocyte differentiation medium one. On day three, replace the supernatants with two milliliters of cardiomyocyte differentiation medium three. On day five.
Replace the supernatant with two milliliters of cardiomyocyte differentiation medium one. On day seven through 10, replace the supernatant with two milliliters of cardiomyocyte differentiation medium four. On days 11 and 13.
When contracting cells are observed, replace the supernatant with two milliliters of cardiomyocyte differentiation medium five. On days 15, 17, 19 and 21. Replace the supernatant with two milliliters of cardiomyocyte differentiation medium four.
After pre-culture with complete blood medium per seven days, PBMC's become large with visible nuclei and cytoplasm indicating that they are ready for transfection with Sendai Virus reprogramming factors. Upon introduction to complete E8 medium. The completely reprogrammed cells will attach and start forming colonies.
After four to five passages, highly pure iPSC colonies will form from the reprogrammed cells with very few differentiated cells observed. At this stage, Most of the cells are OCT4 and NANOG positive indicative of their pluripoteny. Beating cardiomyocytes are usually observed after 12 days of differentiation.
After glucose starvation, and replating iPSC cardiomyocytes exhibits, spontaneous beating, and an aligned sarcomere structure with intercalated cardiac troponin T and alpha actinin expression. The colonies retain their purity as evidenced by their Troponin T expression. Although iPSC cardiomyocytes are relatively immature compared to adult cardiomyocytes.
They demonstrate ventricular and atrial like action potentials as measured by wholesale patch, clamp. Ventricular cardiomyocytes express myosin light chain two, whereas atrial iPSC cardiomyocytes are marked by NR2F2 expression. Wnt activation stimulate cell division and promotes the expression of cell cycle regulators.
Interestingly, Wnt activation also induces the robust proliferation of early iPSC cardiomyocytes for two passages compared to controls, although this proliferative ability diminishes over time. Make sure that the PBMS are enlarged with the clear nuclear and cytoplasm before the iPSC reprogramming vectors are introduced as the condition of the PBMs is critical for iPSC reprogramming. Patient specific cardiomyocytes are valuable for modeling cardiovascular disease in vitro and for providing a ton of donor cells for cardiac stem cell therapy.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol facilitates the generation and expansion of patient-specific cardiomyocytes from peripheral blood mononuclear cells. It is designed to be reproducible and accessible for researchers, especially beginners.
Key Study Components
Area of Science
- Cardiovascular medicine
- Stem cell biology
Background
- Cardiomyocytes are crucial for studying heart diseases.
- Patient-specific cells can enhance disease modeling.
- Peripheral blood mononuclear cells are a non-invasive source.
- Stem cell reprogramming requires careful maintenance.
Purpose of Study
- To develop a protocol for generating cardiomyocytes from blood samples.
- To enable modeling of cardiovascular diseases.
- To test cardiac toxicity of new drugs.
Methods Used
- Collection of peripheral blood mononuclear cells.
- Stem cell reprogramming techniques.
- Directed differentiation into cardiomyocytes.
- Long-term culture maintenance protocols.
Main Results
- Successful generation of patient-specific cardiomyocytes.
- Reproducibility of the protocol for various samples.
- Feasibility for beginners without extensive expertise.
- Potential applications in drug testing and disease modeling.
Conclusions
- This protocol offers a practical approach for researchers.
- It supports advancements in cardiovascular research.
- Future studies can build on this methodology.
Frequently Asked Questions
Executive Industry Relevance
Generating patient-specific cardiomyocytes from peripheral blood mononuclear cells enables scalable, reproducible disease modeling and cardiac toxicity testing. This approach supports early-stage target validation and lead identification by providing human-relevant cellular systems. It reduces reliance on animal models and improves predictive confidence in preclinical cardiovascular research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses using patient-derived cardiomyocytes that reflect genetic disease backgrounds.
- Operational Value: Supports biological de-risking through functional assessment of contractility and electrophysiological properties.
- Predictive Value: Facilitates pathway clarification and mechanistic de-risking of cardiovascular targets prior to lead optimization.
Screening & Assay Development
- Scientific Value: Produces scalable, beating cardiomyocyte populations suitable for high-content functional assays.
- Operational Value: Delivers reproducible, quantitative readouts including calcium transients and field potential duration for compound screening.
- Assay Readiness: Enables standardized, monolayer-based platforms compatible with automated imaging and electrophysiology systems.
Translational & Preclinical Research
- Scientific Value: Models human ventricular and atrial cardiomyocyte phenotypes for disease-relevant mechanism studies.
- Operational Value: Supports longitudinal expansion using CHIR99021 to generate sufficient cell numbers for IND-enabling studies.
- Translational Continuity: Bridges discovery to preclinical validation through consistent, patient-specific cellular systems.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from target validation through lead identification to preclinical safety assessment.
- Discovery Biology: Enables hypothesis testing via directed differentiation of iPSCs into functionally mature cardiomyocyte subtypes.
- Screening: Provides assay-ready, electrically active cardiomyocytes for ion channel and contractility profiling.
- Analytics: Generates action potential and calcium handling data to support comparative compound analysis.
- Translational Research: Maintains phenotypic relevance from iPSC derivation through expansion and characterization.
- Enterprise Reuse: Establishes a scalable, non-invasive cell sourcing workflow applicable across multiple cardiovascular programs.
Operational & Enterprise Impact
- Scientific Value: Increases target validation confidence through human-relevant, genetically matched cellular models.
- Operational Value: Ensures reproducibility and standardization via defined small-molecule differentiation and expansion protocols.
- Strategic Value: Improves go/no-go decisions by enabling early detection of cardiotoxicity liabilities.
- Portfolio Impact: Supports risk-adjusted advancement by reducing translational failure in cardiovascular indications.
Implementation Considerations
- Requires expertise in stem cell culture, iPSC reprogramming, and cardiac differentiation.
- Dependent on defined media, small molecules (CHIR99021), and extracellular matrix-coated platforms.
- Necessitates standardized operating procedures for passaging, differentiation timing, and quality control.
- Requires adaptation monitoring when scaling across different patient-derived iPSC lines.
- Limited by the relative immaturity of iPSC-derived cardiomyocytes compared to adult human counterparts.
